|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06826 HAOHAI BIOTEC
Nominal 
30.700 +0.100 (+0.327%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,634,910 | 25.267% | 2,103,438 | 1,750,116 | 1,324,427 | 1,595,498 |
| Cost of Sales | (781,401) | 19.023% | (656,515) | (490,370) | (334,004) | (363,999) |
| Gross Profit | 1,853,509 | 28.100% | 1,446,923 | 1,259,746 | 990,423 | 1,231,499 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 1,973 | -- | (15,516) | 3,182 | 1,369 | 923 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 456 | -86.990% | 3,505 | 2,193 | (131) | 27,912 | |
| Profit / (Loss) before Taxation | 508,260 | 115.615% | 235,726 | 382,649 | 257,026 | 434,349 | |
| Taxation | (95,991) | 111.457% | (45,395) | (35,366) | (30,686) | (57,972) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,852 | -- | (9,861) | 4,951 | 3,732 | (5,598) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 416,121 | 130.576% | 180,470 | 352,234 | 230,072 | 370,779 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (70,436) | -12.262% | (80,280) | (93,247) | (103,554) | (62,033) |
| Depreciation & Amortisation | 197,855 | -3.115% | 204,217 | 162,837 | 132,871 | 115,427 |
| Directors' Emoluments | 9,007 | -7.278% | 9,714 | 5,621 | 4,850 | 6,450 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 174.286 | 134.615% | 74.286 | 142.857 | 92.857 | 162.143 |
| DPS (cts) | 71.429 | -- | 28.571 | 50.000 | 35.714 | 50.000 |
| Dividend Payout Ratio (%) | 40.984% | -- | 38.462% | 35.000% | 38.462% | 30.837% |
| Cash flow per share ($) | 3.720 | -- | 1.333 | 1.943 | 1.479 | 2.140 |
| NBV per share ($) | 23.535259 | -- | 22.621076 | 23.211219 | 22.13217 | 21.908215 |
| Remarks: | Real time quote last updated: 05/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 235,283 |
| %Change | 14.641% |
| EPS / (LPS) | RMB 1.010 |
| NBV Per Share (¥) | RMB 25.433 |